| Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies (NCT01499147) | University of Illinois at Chicago | 2000-02-01 |
| Efficacy of G-CSF-Priming in Elderly AML Patients (NCT00199147) | Johann Wolfgang Goethe University Hospital | 2000-01-01 |
| Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience. (NCT03350152) | Hospices Civils de Lyon | 2000-01-01 |
| Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2 (NCT00931138) | Acute Leukemia French Association | 1999-12-01 |
| A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. (NCT00363025) | Acute Leukemia French Association | 1999-11-01 |
| An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia (NCT00171249) | Novartis Pharmaceuticals | 1999-08-09 |
| Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) (NCT00266136) | University Hospital Muenster | 1999-06-01 |
| Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies (NCT00038051) | M.D. Anderson Cancer Center | 1999-05-01 |
| Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML) (NCT00880243) | Acute Leukemia French Association | 1999-03-01 |
| L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes (NCT00329498) | Samsung Medical Center | 1998-05-01 |
| Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result (NCT00146120) | University of Ulm | 1998-05-01 |
| Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel (NCT00159003) | Deborah Rund | 1998-01-01 |
| GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly (NCT00925873) | French Innovative Leukemia Organisation | 1996-06-01 |
| Lomustine and Intermediate Dose Cytarabine in Older Patients With AML (NCT00480064) | French Innovative Leukemia Organisation | 1995-07-01 |
| Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission (NCT00667927) | St. Jude Children's Research Hospital | 1991-03-01 |
| Flotetuzumab Expanded Access Program (NCT04678466) | MacroGenics | |
| Expanded Access to ABBV-787 (NCT06439966) | AbbVie | |
| Bone Marrow Angiogenesis in Acute Myeloid Leukemia - Evaluated by Dynamic Contrast Enhanced Magnetic Resonance (MR) Image (NCT00172562) | National Taiwan University Hospital | |
| Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (NCT00037583) | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation (NCT02258490) | Emory University | |
| Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies (NCT07346105) | Orca Biosystems, Inc. | |
| Expanded Access for AG-221 (NCT03723057) | Celgene | |
| Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant (NCT01200017) | Christopher Dvorak | |
| Managed Access Programs for PKC412, Midostaurin (NCT05219266) | Novartis Pharmaceuticals | |
| Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia (NCT01039363) | Samsung Medical Center | |
| Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS (NCT05593185) | Sellas Life Sciences Group | |
| Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation (NCT03245424) | Agios Pharmaceuticals, Inc. | |